Skip to main content
HR 3502 111th Congress House Health Cell biology and embryology Department of Health and Human Services Executive agency funding and structure Genetics Government information and archives Health information and medical records Health programs administration and funding Medical research National Institutes of Health (NIH) Research administration and funding

Mitochondrial Medicine Research and Treatment Enhancement Act

Introduced: July 31, 2009 See on congress.gov
This bill died when the 111th Congress ended
It never became law before the 111th Congress (2009–2010) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 8, 2009
Referred to the Subcommittee on Health.
Jul 31, 2009
Introduced in House
Jul 31, 2009
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Mitochondrial Medicine Research and Treatment Enhancement Act - Amends the Public Health Service Act to establish within the Office of the Director of the National Institutes of Health (NIH) an Office of Mitochondrial Medicine (OMM).

Requires the OMM Director to develop, make publicly available, implement, and biennially update a written plan to facilitate research into mitochondrial medicine. Sets forth as plan objectives: (1) improving coordination of research related to mitochondrial medicine among the national research institutes and between NIH and outside researchers; (2) providing training to research scientists and health professionals engaged in research related to mitochondrial medicine; (3) providing training to health care providers regarding the diagnosis of mitochondrial disease and dysfunction; and (4) establishing scientific review groups with expertise in mitochondrial medicine to oversee relevant research projects in NIH.

Requires the OMM Director to award at least five grants, annually, for each of the following: (1) integrated, multi-project research programs related to mitochondrial medicine; and (2) planning activities associated with such programs.

Authorizes the Director to award grants to institutions or consortiums of institutions to establish Mitochondrial Medicine Centers of Excellence to promote interdisciplinary research and training related to mitochondrial medicine.

Requires the Director to establish: (1) a national registry for the maintenance and sharing for research purposes of medical information collected from patients with mitochondrial disease or dysfunction; and (2) a national biorepository for the maintenance and sharing for research purposes of tissues and DNA collected from such patients.

What's happening now September 8, 2009

Referred to the Subcommittee on Health.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3502: Mitochondrial Medicine Research and Treatment Enhancement Act. 111th Congress. Open America. https://openamerica.io/bill/111-HR-3502/
MLA
"H.R. 3502: Mitochondrial Medicine Research and Treatment Enhancement Act." 111th Congress, 2026, Open America, https://openamerica.io/bill/111-HR-3502/.
Bluebook (legal)
H.R. 3502, 111th Cong. (2026), https://openamerica.io/bill/111-HR-3502/.
Markdown link
[H.R. 3502: Mitochondrial Medicine Research and Treatment Enhancement Act](https://openamerica.io/bill/111-HR-3502/)
Report a problem